Clinical Trial Update: Randomized Phase III Study Of Exemestane (Aromasin) For 5 Years Versus Tamoxifen for 2.5 to 3 Years Followed By Exemestane [Phase 3]

View source ↗

Summary

A randomized Phase III trial comparing five years of exemestane to two-and-a-half to three years of tamoxifen followed by exemestane in breast cancer; results w…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Aromasin (exemestane)
• Nolvadex (tamoxifen)

Snippet

Sponsor: Pfizer | Conditions: Breast Neoplasms | Phase 3 | Status: COMPLETED | Results posted: 2009-12-04